Rotkreuzklinikum München

Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia (2024) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Eissymont O, Crysandt M, et al. Journal article RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial (2023) Link T, Blohmer JU, Schmitt WD, Kuhlmann JD, Just M, Untch M, Stoetzer OJ, et al. Journal article AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaXis and therapy in light of the omicron variants (2023) Giesen N, Busch E, Schalk E, Beutel G, Ruethrich MM, Hentrich M, Hertenstein B, et al. Journal article Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised clinical trial (2023) Issels RD, Boeck S, Pelzer U, Mansmann U, Ghadjar P, Lindner LH, Albertsmeier M, et al. Journal article Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma (2022) Straka C, Schaefer-Eckart K, Hertenstein B, Bassermann F, Salwender H, Langer C, Kroenke J, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution GeparPiPPa- A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC) (2022) Loibl S, Reinisch M, Denkert C, Schneeweiss A, Seiler S, Fasching P, Hanusch C, et al. Conference contribution Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response (2022) Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer JU, Furlanetto J, et al. Journal article Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”: [Annals of Oncology (2019), volume 30:1279-1288, (Annals of Oncology (2019) 30(1279-1288) (S0923753419312785)) (2022) Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, et al. Journal article, Erratum Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution